Humoral and cellular immunogenicity induced by avian influenza A (H7N9) DNA vaccine in mice

Eun Jin Choi, Han Sol Lee, Ji Yun Noh, Joon-Young Song, Hee-Jin Cheong, Ok Shin, Hyojin Lee, Moonsup Jeong, Woo Joo Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: In March 2013, human infection with avian influenza A (H7N9) virus emerged in China, causing serious public health concerns and raising the possibility of avian-source pandemic influenza. Thus, the development of an effective vaccine for preventing and rapidly controlling avian influenza A (H7N9) virus is needed. In this study, we evaluated the immunogenicity of a synthetic DNA vaccine against H7 HA antigens in mice. Materials and Methods: The synthetic consensus H7 HA DNA vaccine (25 or 50 μg) was administered to BALB/c mice at 0, 14, and 28 days by intramuscular injection followed by electroporation. Humoral and cellular immune responses were analyzed in a hemagglutination inhibition test and interferon-gamma enzyme-linked immunospot (ELISpot) assay, respectively. Results: H7 HA-vaccinated mice showed 100% seroprotection and seroconversion rate against H7N9 reassortant influenza virus after both second and third immunizations. The geometric mean titer by the hemagglutination inhibition test increased with an increasing number of immunizations. However, there was no significant difference in geometric titer between the two groups injected with 25 and 50 μg of H7 HA DNA vaccine after two (79.98 vs. 107.65, P = 0.39) and three (159.96 vs. 215.28, P = 0.18) doses. In addition, the ELISpot assay revealed that administration of H7 HA DNA vaccine induced potent interferon-gamma production from mouse splenocytes. Conclusion: This study demonstrated the humoral and cellular immunogenicity of synthetic consensus H7 HA DNA vaccine in mice. This work demonstrates the potential of the H7 HA DNA vaccine as an efficient tool for the rapid control of emerging influenza A (H7N9) virus.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
JournalInfection and Chemotherapy
Volume49
Issue number2
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

DNA Vaccines
Influenza in Birds
H7N9 Subtype Influenza A Virus
Influenza A virus
Hemagglutination Inhibition Tests
Enzyme-Linked Immunospot Assay
Interferon-gamma
Immunization
Reassortant Viruses
Synthetic Vaccines
Electroporation
Intramuscular Injections
Pandemics
Humoral Immunity
Orthomyxoviridae
Cellular Immunity
Human Influenza
China
Vaccines
Public Health

Keywords

  • Cellular immunity
  • DNA vaccine
  • Influenza A(H7N9) virus

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Humoral and cellular immunogenicity induced by avian influenza A (H7N9) DNA vaccine in mice. / Choi, Eun Jin; Lee, Han Sol; Noh, Ji Yun; Song, Joon-Young; Cheong, Hee-Jin; Shin, Ok; Lee, Hyojin; Jeong, Moonsup; Kim, Woo Joo.

In: Infection and Chemotherapy, Vol. 49, No. 2, 01.06.2017, p. 117-122.

Research output: Contribution to journalArticle

@article{8251be458a7145a3bf0581124830259b,
title = "Humoral and cellular immunogenicity induced by avian influenza A (H7N9) DNA vaccine in mice",
abstract = "Background: In March 2013, human infection with avian influenza A (H7N9) virus emerged in China, causing serious public health concerns and raising the possibility of avian-source pandemic influenza. Thus, the development of an effective vaccine for preventing and rapidly controlling avian influenza A (H7N9) virus is needed. In this study, we evaluated the immunogenicity of a synthetic DNA vaccine against H7 HA antigens in mice. Materials and Methods: The synthetic consensus H7 HA DNA vaccine (25 or 50 μg) was administered to BALB/c mice at 0, 14, and 28 days by intramuscular injection followed by electroporation. Humoral and cellular immune responses were analyzed in a hemagglutination inhibition test and interferon-gamma enzyme-linked immunospot (ELISpot) assay, respectively. Results: H7 HA-vaccinated mice showed 100{\%} seroprotection and seroconversion rate against H7N9 reassortant influenza virus after both second and third immunizations. The geometric mean titer by the hemagglutination inhibition test increased with an increasing number of immunizations. However, there was no significant difference in geometric titer between the two groups injected with 25 and 50 μg of H7 HA DNA vaccine after two (79.98 vs. 107.65, P = 0.39) and three (159.96 vs. 215.28, P = 0.18) doses. In addition, the ELISpot assay revealed that administration of H7 HA DNA vaccine induced potent interferon-gamma production from mouse splenocytes. Conclusion: This study demonstrated the humoral and cellular immunogenicity of synthetic consensus H7 HA DNA vaccine in mice. This work demonstrates the potential of the H7 HA DNA vaccine as an efficient tool for the rapid control of emerging influenza A (H7N9) virus.",
keywords = "Cellular immunity, DNA vaccine, Influenza A(H7N9) virus",
author = "Choi, {Eun Jin} and Lee, {Han Sol} and Noh, {Ji Yun} and Joon-Young Song and Hee-Jin Cheong and Ok Shin and Hyojin Lee and Moonsup Jeong and Kim, {Woo Joo}",
year = "2017",
month = "6",
day = "1",
doi = "10.3947/ic.2017.49.2.117",
language = "English",
volume = "49",
pages = "117--122",
journal = "Infection and Chemotherapy",
issn = "2093-2340",
publisher = "Taehan Kamyom Hakhoe, Taehan Hwahak Yopop Hakhoe",
number = "2",

}

TY - JOUR

T1 - Humoral and cellular immunogenicity induced by avian influenza A (H7N9) DNA vaccine in mice

AU - Choi, Eun Jin

AU - Lee, Han Sol

AU - Noh, Ji Yun

AU - Song, Joon-Young

AU - Cheong, Hee-Jin

AU - Shin, Ok

AU - Lee, Hyojin

AU - Jeong, Moonsup

AU - Kim, Woo Joo

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: In March 2013, human infection with avian influenza A (H7N9) virus emerged in China, causing serious public health concerns and raising the possibility of avian-source pandemic influenza. Thus, the development of an effective vaccine for preventing and rapidly controlling avian influenza A (H7N9) virus is needed. In this study, we evaluated the immunogenicity of a synthetic DNA vaccine against H7 HA antigens in mice. Materials and Methods: The synthetic consensus H7 HA DNA vaccine (25 or 50 μg) was administered to BALB/c mice at 0, 14, and 28 days by intramuscular injection followed by electroporation. Humoral and cellular immune responses were analyzed in a hemagglutination inhibition test and interferon-gamma enzyme-linked immunospot (ELISpot) assay, respectively. Results: H7 HA-vaccinated mice showed 100% seroprotection and seroconversion rate against H7N9 reassortant influenza virus after both second and third immunizations. The geometric mean titer by the hemagglutination inhibition test increased with an increasing number of immunizations. However, there was no significant difference in geometric titer between the two groups injected with 25 and 50 μg of H7 HA DNA vaccine after two (79.98 vs. 107.65, P = 0.39) and three (159.96 vs. 215.28, P = 0.18) doses. In addition, the ELISpot assay revealed that administration of H7 HA DNA vaccine induced potent interferon-gamma production from mouse splenocytes. Conclusion: This study demonstrated the humoral and cellular immunogenicity of synthetic consensus H7 HA DNA vaccine in mice. This work demonstrates the potential of the H7 HA DNA vaccine as an efficient tool for the rapid control of emerging influenza A (H7N9) virus.

AB - Background: In March 2013, human infection with avian influenza A (H7N9) virus emerged in China, causing serious public health concerns and raising the possibility of avian-source pandemic influenza. Thus, the development of an effective vaccine for preventing and rapidly controlling avian influenza A (H7N9) virus is needed. In this study, we evaluated the immunogenicity of a synthetic DNA vaccine against H7 HA antigens in mice. Materials and Methods: The synthetic consensus H7 HA DNA vaccine (25 or 50 μg) was administered to BALB/c mice at 0, 14, and 28 days by intramuscular injection followed by electroporation. Humoral and cellular immune responses were analyzed in a hemagglutination inhibition test and interferon-gamma enzyme-linked immunospot (ELISpot) assay, respectively. Results: H7 HA-vaccinated mice showed 100% seroprotection and seroconversion rate against H7N9 reassortant influenza virus after both second and third immunizations. The geometric mean titer by the hemagglutination inhibition test increased with an increasing number of immunizations. However, there was no significant difference in geometric titer between the two groups injected with 25 and 50 μg of H7 HA DNA vaccine after two (79.98 vs. 107.65, P = 0.39) and three (159.96 vs. 215.28, P = 0.18) doses. In addition, the ELISpot assay revealed that administration of H7 HA DNA vaccine induced potent interferon-gamma production from mouse splenocytes. Conclusion: This study demonstrated the humoral and cellular immunogenicity of synthetic consensus H7 HA DNA vaccine in mice. This work demonstrates the potential of the H7 HA DNA vaccine as an efficient tool for the rapid control of emerging influenza A (H7N9) virus.

KW - Cellular immunity

KW - DNA vaccine

KW - Influenza A(H7N9) virus

UR - http://www.scopus.com/inward/record.url?scp=85021705949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021705949&partnerID=8YFLogxK

U2 - 10.3947/ic.2017.49.2.117

DO - 10.3947/ic.2017.49.2.117

M3 - Article

AN - SCOPUS:85021705949

VL - 49

SP - 117

EP - 122

JO - Infection and Chemotherapy

JF - Infection and Chemotherapy

SN - 2093-2340

IS - 2

ER -